Literature DB >> 7688027

Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity.

E I Peerschke1, K B Reid, B Ghebrehiwet.   

Abstract

C1q receptors (C1qR) have been identified on a variety of somatic and cultured cells including peripheral blood platelets. Since platelets are likely to encounter both circulating C1q multimers and C1q associated with the extracellular matrix after complement activation by the classical pathway, the present study was designed to assess the effect of fluid phase and immobilized C1q on platelet function. Platelet adhesion to C1q-coated surfaces was accompanied by the induction of fibrinogen receptors. Scatchard analysis of fibrinogen binding to adherent platelets revealed the binding of approximately 10,000 molecules of fibrinogen per platelet with a Kd of 0.1 +/- 0.03 microM (mean +/- SD, n = 4). Furthermore, fluid phase C1q multimers were noted to aggregate platelets at doses > 5 micrograms/ml. This aggregation was preceded by a rise in inositol-1,4,5-trisphosphate (IP3) (6.9 +/- 2.4 pmoles/10(9) platelets at 15 s, n = 4), and activation of GPIIb-IIIa complexes supporting fibrinogen binding. Platelet aggregation in response to C1q multimers was accompanied by the aspirin-inhibitable release of granule contents and P-selectin (CD62) expression. Platelet aggregation was inhibited by the collagenous domain of C1q (c-Clq) and a monoclonal antibody directed against C1q receptors, suggesting the direct involvement of the 67-kD platelet C1qR. Antibodies against the very late antigen 2 or CD36 collagen receptors were without effect. Platelet exposure to C1q multimers was also accompanied by the expression of procoagulant activity, as demonstrated by the dose-dependent shortening of the kaolin recalcification time of normal plasma from 108 +/- 12 s in the presence of unstimulated platelets to 62 +/- 14 s in the presence of platelets that had been preincubated (5 min, 37 degrees C) with 100 micrograms/ml multimeric C1q (n = 3). These data suggest that platelet interactions with C1q multimers or immobilized C1q, resulting in the activation of GPIIb-IIIa fibrinogen binding sites and the expression of P-selectin as well as platelet procoagulant activity, are likely to contribute to thrombotic events associated with complement activation and inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688027      PMCID: PMC2191135          DOI: 10.1084/jem.178.2.579

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion.

Authors:  N N Tandon; U Kralisz; G A Jamieson
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

Review 2.  Chemistry and molecular genetics of C1q.

Authors:  K B Reid
Journal:  Behring Inst Mitt       Date:  1989-07

3.  Complement subcomponent C1q secreted by cultured human monocytes has subunit structure identical with that of serum C1q.

Authors:  A J Tenner; D B Volkin
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

4.  Platelet IgG Fc receptor.

Authors:  J G Kelton; J W Smith; A V Santos; W G Murphy; P Horsewood
Journal:  Am J Hematol       Date:  1987-07       Impact factor: 10.047

5.  Free platelet count and size distribution during C1q inhibition of collagen-induced platelet aggregation.

Authors:  G Csako; E A Suba
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

6.  Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins.

Authors:  B S Coller; J H Beer; L E Scudder; M H Steinberg
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

7.  Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury.

Authors:  R D Rossen; J L Swain; L H Michael; S Weakley; E Giannini; M L Entman
Journal:  Circ Res       Date:  1985-07       Impact factor: 17.367

8.  Human blood platelets possess specific binding sites for C1q.

Authors:  E I Peerschke; B Ghebrehiwet
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

9.  Production and characterization of a murine monoclonal IgM antibody to human C1q receptor (C1qR).

Authors:  B Ghebrehiwet
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

10.  Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes.

Authors:  J C Bensa; A Reboul; M G Colomb
Journal:  Biochem J       Date:  1983-11-15       Impact factor: 3.857

View more
  23 in total

Review 1.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

Review 2.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

3.  Influence of nanoporesize on platelet adhesion and activation.

Authors:  Natalia Ferraz; Jan Carlsson; Jaan Hong; Marjam Karlsson Ott
Journal:  J Mater Sci Mater Med       Date:  2008-04-15       Impact factor: 3.896

4.  gC1q-R/p32, a C1q-binding protein, is a receptor for the InlB invasion protein of Listeria monocytogenes.

Authors:  L Braun; B Ghebrehiwet; P Cossart
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

5.  C1q-bearing immune complexes induce IL-8 secretion in human umbilical vein endothelial cells (HUVEC) through protein tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms: evidence that the 126 kD phagocytic C1q receptor mediates immune complex activation of HUVEC.

Authors:  S Xiao; C Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

6.  Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction.

Authors:  Sebastian Szabo; Diana Etzel; Raila Ehlers; Thomas Walter; Silke Kazmaier; Uwe Helber; Hans Martin Hoffmeister
Journal:  J Thromb Thrombolysis       Date:  2005-12       Impact factor: 2.300

Review 7.  Signaling pathways and intervention therapies in sepsis.

Authors:  Yun-Yu Zhang; Bo-Tao Ning
Journal:  Signal Transduct Target Ther       Date:  2021-11-25

8.  Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model.

Authors:  J M Cruzado; J Torras; M Riera; N Lloberas; I Herrero; E Condom; J Martorell; J Alsina; J M Grinyó
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

9.  Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage.

Authors:  Matthew C Garrett; Marc L Otten; Robert M Starke; Ricardo J Komotar; Paola Magotti; John D Lambris; Michal A Rynkowski; E Sander Connolly
Journal:  Brain Res       Date:  2009-05-04       Impact factor: 3.252

Review 10.  Platelet mediated complement activation.

Authors:  Ellinor I B Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.